giant cell arteritis market size

• Giant Cell Arteritis (GCA) is a heterogeneous vasculitic disorder that commonly presents with new-onset temporal headache, scalp tenderness, jaw claudication, visual disturbances (including transient or permanent vision loss), and constitutional symptoms such as fatigue, fever, and weight loss, while large-vessel involvement may additionally lead to limb claudication or aortic complications. 
• Polymyalgia Rheumatica (PMR) is a recognized risk factor for GCA, with approximately 15% PMR patients developing GCA and about half of GCA patients exhibiting PMR symptoms.
• GCA typically affects the arteries in the neck and scalp, especially the temples. It frequently affects the aorta and its large branches to the head, arms, and legs. GCA is the most common form of vasculitis in adults over the age of 50.
• GCA diagnosis is based on clinical assessment, inflammatory markers and confirmatory biopsy or advanced imaging, whose increasing use has improved early detection and recognition of previously underdiagnosed disease phenotypes. E
• Epidemiological imaging studies suggest that up to nearly half of patients may have large-vessel involvement, including the aorta and its major branches, which can be clinically silent and therefore underdiagnosed without advanced imaging modalities such as PET-CT or MRI.
• The management of GCA is centered on rapid initiation of high-dose glucocorticoids to prevent irreversible ischemic complications, followed by gradual tapering, with adjunctive use of steroid-sparing agents in selected patients to reduce long-term toxicity.
• Targeted biologic therapy, particularly interleukin-6 receptor inhibition with tocilizumab, has demonstrated efficacy in sustaining remission and reducing cumulative steroid exposure, while emerging therapies including JAK inhibitors are under investigation to further improve disease control. 
• Tocilizumab (ACTEMRA) was the first FDA-approved therapy for giant cell arteritis (GCA), while Upadacitinib (RINVOQ) subsequently expanded the treatment landscape with FDA approval supported by positive Phase III SELECT-GCA efficacy data. 
• Despite therapeutic advancements, GCA remains a serious systemic inflammatory disorder associated with substantial morbidity, high relapse rates, and significant treatment-related toxicity, particularly from prolonged corticosteroid exposure, representing an ongoing unmet clinical need for safer long-term disease management strategies.

GCA Market Size and Forecast in the 7MM

• 2025 GCA Market Size: ~USD XX million
• 2036 Projected GCA Market Size: ~USD XX million
• GCA Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Giant Cell Arteritis (GCA) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the GCA, historical and forecasted epidemiology, as well as the GCA market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The GCA market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates GCA patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in GCA and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the GCA Market

Increasing Disease Burden in an Ageing Population (Epidemiology-Driven Growth)

GCA is strongly age-associated, primarily affecting individual’s ≥50 years, with peak incidence in those aged 70–80 years. Epidemiological studies consistently show rising prevalence in regions with ageing demographics, particularly Northern Europe and North America, which directly expands the diagnosed patient pool and treatment demand.

Shift toward Steroid-Sparing Biologic Therapies (Treatment Paradigm Change)

Long-term glucocorticoids remain the standard first-line therapy but are associated with significant toxicity. This has driven adoption of tocilizumab (ACTEMRA), which is the only widely approved biologic for GCA and demonstrated sustained remission and reduced steroid exposure in the pivotal GiACTA trial.

High Unmet Need Due to Steroid-Related Morbidity and Relapse Risk

Published studies report that a significant proportion of patients experience relapse during steroid tapering, with long-term glucocorticoid-related adverse events (osteoporosis, diabetes, cardiovascular risk, infections) occurring in over half of treated patients. This creates a strong unmet need for safer long-term maintenance therapies and steroid-sparing strategies.

Giant Cell Arteritis (GCA) Understanding and Treatment Algorithm

Giant Cell Arteritis (GCA) Overview and Diagnosis

GCA is an immune-mediated large-vessel vasculitis affecting individuals over 50 years, driven by abnormal immune activation likely triggered by genetic and environmental factors. The disease causes inflammation of arterial walls, leading to vessel narrowing and reduced blood flow. GCA diagnosis is based on clinical evaluation supported by elevated inflammatory markers, including Erythrocyte Sedimentation Rate (ESR) and C - reactive protein (CRP). Confirmation is achieved through temporal artery biopsy, which remains the diagnostic gold standard. Imaging techniques such as vascular ultrasound (halo sign), MRI, and PET are increasingly used to detect cranial and large-vessel involvement, enabling earlier and less invasive diagnosis.

Giant Cell Arteritis (GCA) Diagnosis

Diagnosis of GCA is based on clinical assessment, supported by elevated inflammatory markers such as ESR and CRP. Temporal artery biopsy remains the gold standard for confirmation, demonstrating granulomatous inflammation and multinucleated giant cells. Increasingly, non-invasive imaging is used to support early diagnosis, including vascular ultrasound (halo sign), MRI, and PET, which help detect large-vessel involvement. Diagnosis is often challenging due to nonspecific symptoms, leading to delayed recognition. Therefore, there is strong emphasis on early imaging-based diagnosis and prompt initiation of corticosteroid therapy to prevent irreversible vision loss.

Further details are provided in the report.

Giant Cell Arteritis (GCA) Treatment 

Treatment of GCA is centered on rapid suppression of vascular inflammation to prevent complications such as irreversible vision loss. High-dose corticosteroids (e.g., prednisone or intravenous methylprednisolone in cases with visual symptoms) remain the first-line and standard of care, and are initiated immediately upon clinical suspicion without waiting for biopsy confirmation. To reduce long-term steroid exposure, tocilizumab (ACTEMRA), an IL-6 receptor inhibitor, is the only widely approved steroid-sparing biologic therapy and has demonstrated efficacy in maintaining remission and reducing relapse rates. In selected patients, methotrexate may be used as an adjunct steroid-sparing immunosuppressant, although its efficacy is modest compared to biologics.

Overall, treatment is individualized and long-term, focusing on rapid disease control, prevention of relapse, and minimization of corticosteroid-related toxicity, with increasing adoption of biologic-based steroid-sparing strategies in clinical practice.

 Further details related to country-based variations are provided in the report.

Giant Cell Arteritis (GCA) Unmet Needs

The section “unmet needs of GCA” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

1. High dependence on long-term corticosteroids with significant toxicity burden.

2. Persistent risk of disease relapse despite available treatments

3. Limited availability of steroid-sparing therapeutic options

4. Delayed diagnosis leading to irreversible complications

5. Limited innovation in emerging therapies, and others…..

Note: Comprehensive unmet needs insights in GCA and their strategic implications are provided in the full report.

Giant Cell Arteritis (GCA) Epidemiology

Key Findings from GCA Epidemiological Analysis and Forecast 

• GCA is the most common primary systemic vasculitis in adults over 50 years, with incidence increasing sharply with advancing age. Epidemiological studies consistently show that the disease is strongly age-dependent, with the highest burden observed in individuals in their seventh and eighth decades of life (around 70–80 years), while cases below 50 years are rare.
• GCA affects approximately 100 people per million worldwide and around 20 per 100,000 individuals in the United States. 
• GCA typically develops after the age of 50, is most common among individuals aged 70–79 years, is rare in children, occurs about twice as frequently in females as in males, and is more prevalent among people of Northern European ancestry.
• The incidence of GCA demonstrates significant geographic variation, with higher rates reported in Northern European populations, typically ranging from approximately 10–30 per 100,000 individuals aged 50 years and above, whereas lower number of cases is observed in Southern Europe and Asian populations. This variation is well documented in population-based registries and is thought to reflect both genetic susceptibility and environmental influences.
• GCA shows a clear female predominance, with women being affected approximately two to three times more frequently than men, as consistently reported across multiple cohort studies and registry data analyses.
• Overall, despite being a relatively rare disease in absolute terms, GCA represents a clinically significant burden in the elderly population, with increasing recognition driven by improved diagnostic imaging and heightened clinical awareness in rheumatology practice.

Giant Cell Arteritis (GCA) Drug Analysis & Competitive Landscape

The GCA drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I–III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the GCA treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the GCA therapeutics market.

Approved Therapies for GCA 

Tocilizumab (ACTEMRA) – Roche

Tocilizumab (ACTEMRA), a humanized interleukin-6 (IL-6) receptor antagonist, is approved in the US for the treatment of adult patients with Giant Cell Arteritis (GCA), in combination with a glucocorticoid taper. It is indicated to reduce disease activity and relapse risk while lowering cumulative corticosteroid exposure. Its mechanism involves inhibition of IL-6 receptor signaling, thereby suppressing downstream inflammatory pathways involved in autoimmune disease.

Tocilizumab (ACTEMRA/ROACTEMRA) reported a 4% sales decline in Q1 2026, primarily driven by increasing biosimilar competition, especially in Europe, although the product continues to maintain a significant presence in inflammatory disease markets, including GCA. 

Note: Detailed marketed therapies assessment of therapies will be provided in the final report.

Note: Detailed emerging therapies assessment will be provided in the final report.

GCA Key Players, Market Leaders, and Emerging Companies

• AbbVie 
• Roche

GCA Drug Updates 

• In April 2026, Gedeon Richter received European Commission approval for Tuyory (tocilizumab biosimilar), available in both IV and SC formulations for multiple indications, including giant cell arteritis (GCA). 
• In March 2026, Celltrion launched the SC formulation of Avtozma in the US for multiple indications, including GCA, offering convenient prefilled syringe and autoinjector delivery options.
• In July 2025, Novartis’ secukinumab failed to meet the primary endpoint of sustained remission at Week 52 in the Phase III GCAptAIN trial in patients with GCA. 
• In April 2025, AbbVie announced The European Commission (EC) has granted marketing authorization to Upadacitinib (RINVOQ 15 mg, once daily) for the treatment of GCA in adult patients. This approval establishes RINVOQ as the first and only oral Janus kinase (JAK) inhibitor approved in the European Union.
• In April 2025, AbbVie announced The US Food and Drug Administration (FDA) has approved upadacitinib (RINVOQ 15 mg, once daily) for the treatment of adult patients with GCA. This approval follows the recent European Commission marketing authorization for RINVOQ in the same indication, further expanding its availability across major regulated markets. 

Giant Cell Arteritis (GCA) Market Outlook

GCA remains a critical inflammatory vasculitis of older adults, associated with severe complications including irreversible vision loss and large-vessel ischemic events. The treatment paradigm is gradually shifting from prolonged corticosteroid use toward steroid-sparing targeted therapies, reflecting the growing need for safer long-term disease management. While corticosteroids continue to serve as the cornerstone of first-line treatment, their substantial toxicity burden has driven adoption of advanced immunomodulatory therapies. ACTEMRA (tocilizumab) established the first targeted biologic approach through IL-6 inhibition, while the recent approval of RINVOQ (upadacitinib) has further expanded the market by introducing the first oral advanced therapy for GCA.

Despite these advances, the GCA market remains highly concentrated, with only two approved targeted therapies and a limited late-stage pipeline. Several promising candidates have encountered development challenges. Mavrilimumab demonstrated positive Phase II efficacy, significantly reducing disease flares and improving sustained remission; however, development was not advanced further as Kiniksa Pharmaceuticals shifted its strategic focus toward its commercial product ARCALYST and other pipeline assets, including KPL-404, and subsequently sought collaborative partnerships to further advance mavrilimumab in rare cardiovascular and autoimmune diseases. Similarly, secukinumab (COSENTYX) was discontinued in GCA following the failure of the Phase III GCAptAIN trial to meet its primary endpoint. These setbacks highlight the complexity of GCA drug development and reinforce the substantial unmet need for therapies capable of delivering durable disease control with reduced corticosteroid exposure.

Overall, the GCA market remains an innovation-constrained but evolving landscape, with growth expected to be driven by improved diagnosis rates, longer treatment duration, and increasing uptake of tocilizumab and upadacitinib, rather than significant pipeline expansion. The scarcity of advanced-stage pipeline assets underscores the need for next-generation disease modifying therapies that can provide sustained remission, improved safety, and meaningful steroid sparing benefits.

• Current market revenues are largely driven by approved enzyme replacement therapies, particularly in patients with severe disease manifestations and high unmet medical need. 
• Over the long term, emerging disease modifying therapies and next-generation treatment approaches are expected to expand therapeutic options and address remaining treatment gaps, particularly in patients with milder disease phenotypes.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in Giant Cell Arteritis (GCA)  (2022–2036 Forecast)

The GCA treatment landscape comprises corticosteroids and targeted steroid-sparing therapies aimed at controlling vascular inflammation, preventing disease relapse, and improving long-term disease management outcomes.

• IL-6 Receptor Inhibitors: Therapies such as tocilizumab (ACTEMRA) block interleukin-6 (IL-6) signaling, a key driver of systemic and vascular inflammation in GCA. By suppressing IL-6-mediated immune activation, these therapies help achieve sustained remission and reduce corticosteroid dependence. 
• JAK Inhibitors: Therapies such as upadacitinib (RINVOQ) selectively inhibit Janus kinase (JAK) signaling pathways involved in the activity of multiple pro-inflammatory cytokines. This mechanism helps control vascular inflammation and disease activity while supporting steroid-sparing treatment strategies.

Overall, corticosteroids remain the backbone of GCA management, while tocilizumab and upadacitinib have introduced targeted steroid-sparing approaches, and supportive care strategies continue to play a key role in improving long-term patient outcomes.

Giant Cell Arteritis (GCA) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the GCA drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in GCA is expected to remain centered on corticosteroids, with gradual growth in steroid-sparing targeted therapies and limited overall expansion beyond current standards. Corticosteroids is expected continue to dominate as first-line therapy, driven by rapid disease control and prevention of acute complications such as vision loss, despite well-recognized long-term safety concerns. Tocilizumab (ACTEMRA) and Upadacitinib (RINVOQ) are expected to show increasing uptake as targeted steroid-sparing therapies, supported by their ability to reduce relapse risk and cumulative steroid exposure and enable improved long-term disease management. Uptake remains gradual due to the rarity of the disease and concentrated treatment pathways.

Supportive therapies will maintain stable usage, primarily focused on managing steroid-related adverse effects and cardiovascular risk reduction. Overall, GCA treatment uptake remains highly corticosteroid-dependent, with gradual adoption of biologic and oral targeted therapies, and growth driven mainly by increased diagnosis rates and longer treatment duration, rather than pipeline-driven expansion.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Giant Cell Arteritis (GCA)  

• The United States

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc. 

NOTE: Further Details are provided in the final report….

Giant Cell Arteritis (GCA) Therapies Price Scenario & Trends 

Pricing and analogue assessment of GCA therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report….

Industry Experts and Physician Views for Giant Cell Arteritis (GCA)

To keep up with GCA market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging GCA therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in GCA, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the Desert Regional Medical Center, USA, University of Lübeck, Germany   etc., were contacted. Their opinion helps understand and validate current and emerging GCA therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in GCA.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT analysis of GCA, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of GCA, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the GCA market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM GCA market. 

Report Insights

• Giant Cell Arteritis (GCA) Patient Population Forecast
• Giant Cell Arteritis (GCA) Therapeutics Market Size 
• Giant Cell Arteritis (GCA) Pipeline Analysis
• Giant Cell Arteritis (GCA) Market Size and Trends
• Giant Cell Arteritis (GCA) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Giant Cell Arteritis (GCA) Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Giant Cell Arteritis (GCA) Treatment Addressable Market (TAM)
• Giant Cell Arteritis (GCA) Competitive Landscape
• Giant Cell Arteritis (GCA) Major Companies Insights
• Giant Cell Arteritis (GCA) Price Trends and Analogue Assessment
• Giant Cell Arteritis (GCA) Therapies Drug Adoption/Uptake
• Giant Cell Arteritis (GCA) Therapies Peak Patient Share Analysis

Report Assessment

• Giant Cell Arteritis (GCA) Current Treatment Practices
• Giant Cell Arteritis (GCA) Unmet Needs
• Giant Cell Arteritis (GCA) Clinical Development Analysis
• Giant Cell Arteritis (GCA) Emerging Drugs Product Profiles
• Giant Cell Arteritis (GCA) Market Attractiveness
• Giant Cell Arteritis (GCA) Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the GCA market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of GCA?
• What are the disease risks, burdens, and unmet needs of GCA? What will be the growth opportunities across the 7MM concerning the patient population with GCA?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of GCA? What are the current guidelines for treating GCA in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the GCA market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.